Platform evolution, guided by discipline and clinical evidence
Meibum Scientific’s pipeline reflects a deliberate, mechanism-based approach to platform development, balancing real-world clinical use with long-term scientific rigor.
REVVE Protocol
Meibum Scientific’s current platform is centered on the REVVE protocol, a protocolized framework designed to address biofilm-driven meibomian gland disease. The protocol is actively used in clinical practice and continues to be refined through real-world observation and outcome tracking.
- Used in clinical practice with protocolized sequencing
- Refined through observation and outcome tracking
- Focused on mechanism-driven disease control
Clinical Optimization
Near-term development efforts are focused on expanding clinical adoption, optimizing treatment intervals, standardizing outcome assessment, and supporting clinician education. These initiatives are intended to improve consistency of care and deepen understanding of disease response.
- Broaden clinical adoption
- Optimize treatment intervals
- Standardize outcome assessment
- Support clinician education
Platform Extension
Longer-term development includes exploration of next-generation tools, expanded indications, and adjacent applications of biofilm-targeting science. Future efforts will be guided by clinical need, scientific validation, and disciplined execution.
- Next-generation tools
- Expanded indications
- Adjacent applications
- Driven by clinical need and validation
This overview is intentionally conservative and sequencing-focused, reflecting platform discipline rather than speculative timelines.